AZD4721 Solution + AZD4721 Placebo + AZD4721 Suspension
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax
Conditions
Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax
Trial Timeline
Jul 1, 2013 → Dec 1, 2013
NCT ID
NCT01889160About AZD4721 Solution + AZD4721 Placebo + AZD4721 Suspension
AZD4721 Solution + AZD4721 Placebo + AZD4721 Suspension is a phase 1 stage product being developed by AstraZeneca for Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax. The current trial status is completed. This product is registered under clinical trial identifier NCT01889160. Target conditions include Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax.
What happened to similar drugs?
3 of 4 similar drugs in Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax were approved
Approved (3) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01889160 | Phase 1 | Completed |
Competing Products
20 competing products in Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax